Side Effects
Less common
- Transient lipase elevations
Serious but rare
- Acute pancreatitis (1 case in Phase 2) - discontinue if suspected
- Gallbladder disorders (cholelithiasis, cholecystitis)
- Hypersensitivity reactions
Class-level context
Retatrutide has no approved label. Trial exclusions and warnings known from approved GLP-1 medicines are useful context, but they should not be presented as Retatrutide-specific approved contraindications.
What this evidence review covers
Summarize adverse events observed in Retatrutide trials and distinguish known trial signals from unknown retail-product risks.
- Phase 2 obesity adverse-event table
- Type 2 diabetes adverse events
- Dose-escalation context and discontinuations
- What is unknown about longer-term use
- Product-quality and identity risks outside trials
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
direct human evidence
Gastrointestinal adverse events were the most common reported events in the phase 2 programs.
entity boundary
Retail-product risk cannot be estimated from trial safety data because identity and quality equivalence are not established.
| Evidence class | What the source supports |
|---|---|
| direct human evidence | Gastrointestinal adverse events were the most common reported events in the phase 2 programs. |
| entity boundary | Retail-product risk cannot be estimated from trial safety data because identity and quality equivalence are not established. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Evidence class: primary randomized phase 2. What it supports: n=338 obesity/overweight trial; receptor description; dose arms; 24- and 48-week weight outcomes; reported adverse events.
What it does not establish: Approved use, long-term benefit-risk, vendor-product equivalence, cross-trial superiority, or a consumer protocol.
Retatrutide in people with type 2 diabetes - randomized phase 2 trial
Evidence class: primary randomized phase 2. What it supports: n=281 type 2 diabetes trial; HbA1c and body-weight endpoints; gastrointestinal-event reporting.
What it does not establish: Outcomes in people without diabetes, an approved indication, or retail-product equivalence.
FDA concerns with unapproved GLP-1 drugs used for weight loss
Evidence class: primary regulatory. What it supports: Retatrutide and cagrilintide are not components of approved drugs, have not been found safe and effective, and cannot be used in compounding under federal law; FDA warnings about false research labels.
What it does not establish: A general claim that every observed listing is unlawful in every jurisdiction.
Questions this page answers
What side effects were reported in trials?
Summarize only event categories and frequencies actually reported in the cited trial, with arm and duration context.
Is online Retatrutide safe if the trial looked tolerable?
The trial cannot answer that; it did not test an unverified vendor vial.
What remains unresolved
- Long-term and rare-event certainty remains incomplete.
- Sponsor topline safety needs a full peer-reviewed source before granular claims.
- No product-level pharmacovigilance dataset for tracked vendors.